Rhythm Pharmaceuticals raises $50M via ATM equity offering of 2M shares

RHYTHM PHARMACEUTICALS, INC.

Sold ~2.019M shares of common stock from Aug 10-21, 2023, for gross proceeds of ~$50M.
Proceeds, plus existing cash and anticipated $24.4M milestone from Healthcare Royalty Partners, fund operations into 2026.
Funds to support global commercialization of IMCIVREE (setmelanotide) and rare MC4R pathway clinical programs.
ATM program originally authorized up to $100M; this drawdown represents half the capacity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.